JP2022513379A5 - - Google Patents

Info

Publication number
JP2022513379A5
JP2022513379A5 JP2021547607A JP2021547607A JP2022513379A5 JP 2022513379 A5 JP2022513379 A5 JP 2022513379A5 JP 2021547607 A JP2021547607 A JP 2021547607A JP 2021547607 A JP2021547607 A JP 2021547607A JP 2022513379 A5 JP2022513379 A5 JP 2022513379A5
Authority
JP
Japan
Prior art keywords
msc
polypeptide
seq
promoter
aoah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513379A (ja
JP7372982B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/051526 external-priority patent/WO2020087160A1/en
Publication of JP2022513379A publication Critical patent/JP2022513379A/ja
Publication of JP2022513379A5 publication Critical patent/JP2022513379A5/ja
Application granted granted Critical
Publication of JP7372982B2 publication Critical patent/JP7372982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547607A 2018-10-29 2019-10-29 Aoahを過剰発現する遺伝子組換え間葉系幹細胞及びその使用 Active JP7372982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752000P 2018-10-29 2018-10-29
US62/752,000 2018-10-29
PCT/CA2019/051526 WO2020087160A1 (en) 2018-10-29 2019-10-29 Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof

Publications (3)

Publication Number Publication Date
JP2022513379A JP2022513379A (ja) 2022-02-07
JP2022513379A5 true JP2022513379A5 (cg-RX-API-DMAC7.html) 2022-08-05
JP7372982B2 JP7372982B2 (ja) 2023-11-01

Family

ID=70462996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547607A Active JP7372982B2 (ja) 2018-10-29 2019-10-29 Aoahを過剰発現する遺伝子組換え間葉系幹細胞及びその使用

Country Status (10)

Country Link
US (1) US20220010281A1 (cg-RX-API-DMAC7.html)
EP (1) EP3874029B1 (cg-RX-API-DMAC7.html)
JP (1) JP7372982B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210086662A (cg-RX-API-DMAC7.html)
CN (1) CN113166729A (cg-RX-API-DMAC7.html)
AU (1) AU2019370629A1 (cg-RX-API-DMAC7.html)
ES (1) ES2962812T3 (cg-RX-API-DMAC7.html)
IL (1) IL282820A (cg-RX-API-DMAC7.html)
SG (1) SG11202103509RA (cg-RX-API-DMAC7.html)
WO (1) WO2020087160A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302060A (en) * 2020-10-16 2023-06-01 Ottawa Hospital Res Inst Cell-based therapy for viral diseases
CN116570711A (zh) * 2022-12-21 2023-08-11 上海交通大学医学院附属第九人民医院 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用
WO2026101889A2 (en) * 2024-11-06 2026-05-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Acyloxyacyl hydrolase and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
JP2011528566A (ja) * 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
JP2012529895A (ja) * 2009-06-19 2012-11-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法
EP2626369A1 (en) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Engineered mesenchymal stem cells and their therapeutic use
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
RU2658490C2 (ru) * 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
CA2928852A1 (en) * 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR102213527B1 (ko) * 2014-06-30 2021-02-09 타이제닉스, 에스.에이.유. 패혈증 치료용 중간엽 기질세포
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
CA3172801A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
CN108430480B (zh) * 2015-09-15 2022-08-02 康干细胞生物科技有限公司 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物

Similar Documents

Publication Publication Date Title
JP2022507454A5 (cg-RX-API-DMAC7.html)
JP2023544683A5 (cg-RX-API-DMAC7.html)
JP2019523648A5 (cg-RX-API-DMAC7.html)
JP2023070682A5 (cg-RX-API-DMAC7.html)
JP2017018125A5 (cg-RX-API-DMAC7.html)
JP2018520997A5 (cg-RX-API-DMAC7.html)
JP2019500414A5 (cg-RX-API-DMAC7.html)
JP2009515529A5 (cg-RX-API-DMAC7.html)
TW201625793A (zh) 用於治療溶酶體貯積病之腺相關病毒載體
DE69034122D1 (de) Menschlicher c3b/c4b-rezeptor (cr1)
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2023534924A5 (cg-RX-API-DMAC7.html)
JP2024503091A5 (cg-RX-API-DMAC7.html)
JP2020500162A5 (cg-RX-API-DMAC7.html)
JPWO2019156137A5 (cg-RX-API-DMAC7.html)
JP2014198050A5 (cg-RX-API-DMAC7.html)
JP2018537089A5 (cg-RX-API-DMAC7.html)
JP2020503265A5 (cg-RX-API-DMAC7.html)
JP2022514465A5 (cg-RX-API-DMAC7.html)
JP2020535804A5 (cg-RX-API-DMAC7.html)
JP2023535121A5 (cg-RX-API-DMAC7.html)
JP2020105169A5 (cg-RX-API-DMAC7.html)
WO2014036524A4 (en) Genetically modified msc and therapeutic methods
FI3833746T3 (fi) Mini-GDE glykogenoosi III:n hoitamiseksi
JP2018509909A5 (cg-RX-API-DMAC7.html)